PMID- 19568796 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20110714 LR - 20211020 IS - 1864-6158 (Print) IS - 1864-6166 (Electronic) IS - 1864-6158 (Linking) VI - 1 IP - 1-4 DP - 2008 Nov TI - Rapamycin and mTOR kinase inhibitors. PG - 27-36 LID - 10.1007/s12154-008-0003-5 [doi] AB - Mammalian target of rapamycin (mTOR) is a protein kinase that controls cell growth, proliferation, and survival. mTOR signaling is often upregulated in cancer and there is great interest in developing drugs that target this enzyme. Rapamycin and its analogs bind to a domain separate from the catalytic site to block a subset of mTOR functions. These drugs are extremely selective for mTOR and are already in clinical use for treating cancers, but they could potentially activate an mTOR-dependent survival pathway that could lead to treatment failure. By contrast, small molecules that compete with ATP in the catalytic site would inhibit all of the kinase-dependent functions of mTOR without activating the survival pathway. Several non-selective mTOR kinase inhibitors have been described and here we review their chemical and cellular properties. Further development of selective mTOR kinase inhibitors holds the promise of yielding potent anticancer drugs with a novel mechanism of action. FAU - Ballou, Lisa M AU - Ballou LM AD - Department of Medicine, Stony Brook University, Stony Brook, NY, 11794, USA. FAU - Lin, Richard Z AU - Lin RZ LA - eng GR - R01 DK062722/DK/NIDDK NIH HHS/United States PT - Journal Article DEP - 20080515 PL - Germany TA - J Chem Biol JT - Journal of chemical biology JID - 101318662 PMC - PMC2698317 EDAT- 2009/07/02 09:00 MHDA- 2009/07/02 09:01 PMCR- 2009/11/01 CRDT- 2009/07/02 09:00 PHST- 2008/02/19 00:00 [received] PHST- 2008/03/11 00:00 [accepted] PHST- 2009/07/02 09:00 [entrez] PHST- 2009/07/02 09:00 [pubmed] PHST- 2009/07/02 09:01 [medline] PHST- 2009/11/01 00:00 [pmc-release] AID - 3 [pii] AID - 10.1007/s12154-008-0003-5 [doi] PST - ppublish SO - J Chem Biol. 2008 Nov;1(1-4):27-36. doi: 10.1007/s12154-008-0003-5. Epub 2008 May 15.